News
ALKS
24.50
+0.25%
0.06
ALKERMES ANNOUNCES INITIATION OF VIBRANCE-1 PHASE 2 STUDY EVALUATING ALKS 2680 FOR THE TREATMENT OF NARCOLEPSY TYPE 1
Reuters · 2d ago
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
NASDAQ · 4d ago
Weekly Report: what happened at ALKS last week (0415-0419)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
TipRanks · 04/19 10:30
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Dow Jones · 04/19 10:27
HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target
Benzinga · 04/19 10:17
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
TipRanks · 04/18 05:10
FHLC: Healthcare Dashboard For April
Seeking Alpha · 04/16 20:24
Weekly Report: what happened at ALKS last week (0408-0412)?
Weekly Report · 04/15 09:07
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
TipRanks · 04/12 05:41
Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges
TipRanks · 04/12 05:38
Oversold Conditions For Alkermes (ALKS)
NASDAQ · 04/11 20:25
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
NASDAQ · 04/11 14:15
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)
TipRanks · 04/10 11:20
Balanced Hold Rating for Alkermes Amidst Promising Data and Development Risks
TipRanks · 04/10 10:26
Buy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth Potential
TipRanks · 04/10 00:55
Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Seeking Alpha · 04/09 20:29
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
Alkermes plc revealed topline results from a phase 1b study of ALKS 2680 for narcolepsy. Jefferies increased the probability of success for ALKS-2680 to 50%, with peak sales of $1 billion. The analyst increased the price target from $42 to $50.
Benzinga · 04/09 18:23
BUZZ-U.S. STOCKS ON THE MOVE-Chemours, Lucid, OppFi
U.S. Stocks reverse early gains ahead of key inflation print. Dow Jones Industrial Average down 0.36%; S&P 500 and Nasdaq Composite also down. Chemours, Lucid, OppFi among the top stocks on the move. Lucid Group down 3.9% after announcing potential sale of parts of company.
Reuters · 04/09 18:19
Alkermes on the Rise: A Promising Outlook for Narcolepsy Treatment with ALKS 2680
TipRanks · 04/09 17:05
More
Webull provides a variety of real-time ALKS stock news. You can receive the latest news about Alkermes Plc through multiple platforms. This information may help you make smarter investment decisions.
About ALKS
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.